Sensyne Health plc, the UK Clinical AI company, announces that its SYNE-COVTM machine learning algorithm for COVID risk prediction has achieved regulatory approval for use in the UK.
SYNE-COV analyses over 60 variables in the patient electronic health record to generate a prediction of the likelihood of a COVID positive patient developing severe disease, requiring ventilation or admission to intensive care. It provides the risk prediction, together with an explanation of the result, to help clinicians manage patients admitted to hospital with COVID infection.
The SYNE-COV product was developed in collaboration between Sensyne and the Chelsea & Westminster Hospitals NHS Foundation Trust This is the first algorithm developed from the SENSETM clinical and operational algorithm engine to achieve UK regulatory approval. SENSE generates Clinical AI algorithms (called SYNEs) from the analysis of data in patient electronic health records to provide decision support to clinicians. The Company has several algorithms currently in development across multiple medical conditions, which subject to regulatory approval, it intends to market to healthcare providers in the UK and internationally.
Following regulatory approval, Sensyne is now able to market SYNE-COV across the UK. Sensyne will market the algorithm to NHS Trusts in order to help them with COVID preparedness and to deploy the algorithm in good time for the 2021/22 winter season